Clinical Trial Update: Neoadjuvant Chemotherapy Plus Pyrotinib and Trastuzumab for HER2-positive Breast Cancer (NEOTORCH-BREAST05) [Phase 2]

View source ↗

Summary

Phase 2 neoadjuvant trial NEOTORCH-BREAST05 evaluating chemotherapy plus pyrotinib and trastuzumab for HER2-positive breast cancer is currently recruiting in Ch…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• HERCEPTIN (trastuzumab)
• Tyvyt (Sintilimab)

Snippet

Sponsor: First Affiliated Hospital of Zhejiang University | Conditions: HER2-positive Breast Cancer, Neoadjuvant Therapy | Phase 2 | Status: RECRUITING